RxDoctor Payments Data

Erika Wachs, DO

Family Medicine · Auburn, ALNPI 1871112177

Payments from drug & device makers

$2,130in general payments, 2019–2025

Across 106 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$266
  • Lilly USA, LLC$250
  • AstraZeneca$249
  • Axsome Therapeutics, Inc.$243
  • Pfizer$201
  • Novo Nordisk$185
  • plus $736 from 16 others

What the payments were for

  • Food & beverage$2,130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,130 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$15,351
Medicare patients
50
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide19$18,035
MounjaroTirzepatide11$16,047
EliquisApixaban11$8,867
Rosuvastatin Calcium31$756
Gabapentin42$753
Atorvastatin Calcium66$698
Albuterol Sulfate HfaAlbuterol Sulfate27$690
Losartan Potassium37$460
Levothyroxine Sodium37$393
Omeprazole25$321
Sertraline Hcl29$279
Lisinopril33$275
Amlodipine Besylate58$258
Bupropion XlBupropion Hcl21$234
Fluticasone Propionate17$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$185$18,03519 claims
Lilly USA, LLCMounjaro$250$16,04711 claims
PfizerEliquis$201$8,86711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Auburn

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →